Runde Xiong, Dongxiu He, Xiangping Deng, Juan Liu, Xiaoyong Lei, Zhizhong Xie, Xuan Cao, Yanming Chen, Junmei Peng, Guotao Tang
{"title":"色胺水杨酸衍生物作为潜在抗肿瘤药物的设计、合成和生物学评价。","authors":"Runde Xiong, Dongxiu He, Xiangping Deng, Juan Liu, Xiaoyong Lei, Zhizhong Xie, Xuan Cao, Yanming Chen, Junmei Peng, Guotao Tang","doi":"10.1039/c8md00484f","DOIUrl":null,"url":null,"abstract":"<p><p>A series of tryptamine salicylic acid derivatives were synthesized and their antiproliferative activity against MGC-803, MCF-7, HepG2, A549 and HeLa cell lines was evaluated. The structure-activity relationship (SAR) study revealed that different substitutions of the C5 and C3'-C5' positions have certain effects on the anti-proliferation activity. The growth assay revealed that <b><i>N</i>-[2-(5-bromo-1<i>H</i>-indol-3-yl)-ethyl]-2-hydroxy-3-methyl-benzamide</b> (<b>E20</b>) showed the most potent and broad-spectrum anticancer inhibition of all the cell lines evaluated, and was only more potent than 5-Fu for the gastric cancer cell line. Preliminary studies indicated that compound <b>E20</b> could inhibit colony formation and migration of MGC-803 cells. The flow cytometry (FCM) results showed that compound <b>E20</b> arrested the cell cycle in the G2/M phase and induced apoptosis of MGC-803 cells in a concentration-dependent manner. In addition, the western blot results showed that <b>E20</b> can down-regulate the expression of hexokinase 2. Our studies suggest that the framework of <b><i>N</i>-[2-(5-bromo-1<i>H</i>-indol-3-yl)-ethyl]-2-hydroxy-3-methyl-benzamide</b> may be consider as a new type of chemical for designing effective anti-cancer drugs targeting gastric cancer cells.</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":"10 4","pages":"573-583"},"PeriodicalIF":3.5970,"publicationDate":"2019-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1039/c8md00484f","citationCount":"5","resultStr":"{\"title\":\"Design, synthesis and biological evaluation of tryptamine salicylic acid derivatives as potential antitumor agents.\",\"authors\":\"Runde Xiong, Dongxiu He, Xiangping Deng, Juan Liu, Xiaoyong Lei, Zhizhong Xie, Xuan Cao, Yanming Chen, Junmei Peng, Guotao Tang\",\"doi\":\"10.1039/c8md00484f\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>A series of tryptamine salicylic acid derivatives were synthesized and their antiproliferative activity against MGC-803, MCF-7, HepG2, A549 and HeLa cell lines was evaluated. The structure-activity relationship (SAR) study revealed that different substitutions of the C5 and C3'-C5' positions have certain effects on the anti-proliferation activity. The growth assay revealed that <b><i>N</i>-[2-(5-bromo-1<i>H</i>-indol-3-yl)-ethyl]-2-hydroxy-3-methyl-benzamide</b> (<b>E20</b>) showed the most potent and broad-spectrum anticancer inhibition of all the cell lines evaluated, and was only more potent than 5-Fu for the gastric cancer cell line. Preliminary studies indicated that compound <b>E20</b> could inhibit colony formation and migration of MGC-803 cells. The flow cytometry (FCM) results showed that compound <b>E20</b> arrested the cell cycle in the G2/M phase and induced apoptosis of MGC-803 cells in a concentration-dependent manner. In addition, the western blot results showed that <b>E20</b> can down-regulate the expression of hexokinase 2. Our studies suggest that the framework of <b><i>N</i>-[2-(5-bromo-1<i>H</i>-indol-3-yl)-ethyl]-2-hydroxy-3-methyl-benzamide</b> may be consider as a new type of chemical for designing effective anti-cancer drugs targeting gastric cancer cells.</p>\",\"PeriodicalId\":88,\"journal\":{\"name\":\"MedChemComm\",\"volume\":\"10 4\",\"pages\":\"573-583\"},\"PeriodicalIF\":3.5970,\"publicationDate\":\"2019-01-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1039/c8md00484f\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"MedChemComm\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1039/c8md00484f\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2019/4/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"MedChemComm","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1039/c8md00484f","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/4/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
Design, synthesis and biological evaluation of tryptamine salicylic acid derivatives as potential antitumor agents.
A series of tryptamine salicylic acid derivatives were synthesized and their antiproliferative activity against MGC-803, MCF-7, HepG2, A549 and HeLa cell lines was evaluated. The structure-activity relationship (SAR) study revealed that different substitutions of the C5 and C3'-C5' positions have certain effects on the anti-proliferation activity. The growth assay revealed that N-[2-(5-bromo-1H-indol-3-yl)-ethyl]-2-hydroxy-3-methyl-benzamide (E20) showed the most potent and broad-spectrum anticancer inhibition of all the cell lines evaluated, and was only more potent than 5-Fu for the gastric cancer cell line. Preliminary studies indicated that compound E20 could inhibit colony formation and migration of MGC-803 cells. The flow cytometry (FCM) results showed that compound E20 arrested the cell cycle in the G2/M phase and induced apoptosis of MGC-803 cells in a concentration-dependent manner. In addition, the western blot results showed that E20 can down-regulate the expression of hexokinase 2. Our studies suggest that the framework of N-[2-(5-bromo-1H-indol-3-yl)-ethyl]-2-hydroxy-3-methyl-benzamide may be consider as a new type of chemical for designing effective anti-cancer drugs targeting gastric cancer cells.
期刊介绍:
Research and review articles in medicinal chemistry and related drug discovery science; the official journal of the European Federation for Medicinal Chemistry.
In 2020, MedChemComm will change its name to RSC Medicinal Chemistry. Issue 12, 2019 will be the last issue as MedChemComm.